Clinical Trial Details
| Trial ID: | L2320 |
| Source ID: | NCT00442325 |
| Associated Drug: | Atorvastatin (Lipitor) |
| Title: | Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets |
| Acronym: | ACTFAST 2 |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Coronary Arteriosclerosis|Diabetes Mellitus, Type 2|Cerebrovascular Accident|Dyslipidemia|Peripheral Vascular Disease |
| Interventions: | DRUG: Atorvastatin (Lipitor) |
| Outcome Measures: | Primary: Proportion of subjects achieving a LDL-C target of < 100 mg/dL (2.6 mmol/L) after 12 weeks. | Secondary: Percentage of subjects achieving:|LDL-C target <100 mg/dL (<2.6 mmol/L) after 6 weeks of treatment.|Total cholesterol (TC)/HDL-C ratio target (<4.0) after 6 and 12 weeks of treatment.|Either the LDL-C <100mg/dL (<2.6 mmol/L) or TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment.|Both the LDL-C <100mg/dL (<2.6 mmol/L) and TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment.|LDL-C <100mg/dL (<2.6 mmol/L) or TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment by LDL-C strata.|LDL-C target (<100 mg/dL) by primary inclusion diagnosis (CHD, CHD-equivalent, diabetes or 10-year CHD risk-equivalent >20%).|The mean percent change in LDL-C, high density lipoprotein cholesterol (HDL-C),TC/HDL-C ratio, non HDL-C (in subjects with triglycerides [TG] ≥200 mg/dL or 2.3 mmol/L), TC and TG from baseline to 6 and 12 weeks of treatment. Change from baseline in apol |
| Sponsor/Collaborators: | Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE4 |
| Enrollment: | 595 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2003-01 |
| Completion Date: | 2004-02 |
| Results First Posted: | |
| Last Update Posted: | 2021-02-18 |
| Locations: | Pfizer Investigational Site, Ioannina, Greece|Pfizer Investigational Site, Kallithea, Athens, Greece|Pfizer Investigational Site, Pireaus, Greece|Pfizer Investigational Site, Thessaloniki, Greece|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Gyula, Hungary|Pfizer Investigational Site, Kecskemet, Hungary|Pfizer Investigational Site, Nyíregyháza, Hungary|Pfizer Investigational Site, Szekszárd, Hungary|Pfizer Investigational Site, Tullamore, CO. Offlay, Ireland|Pfizer Investigational Site, Tallaght, Dublin, Ireland|Pfizer Investigational Site, Gorey, Wexford, Ireland|Pfizer Investigational Site, Cork, Ireland|Pfizer Investigational Site, Dublin 8, Ireland|Pfizer Investigational Site, Dublin, Ireland|Pfizer Investigational Site, Galway, Ireland|Pfizer Investigational Site, Czestochowa, Poland|Pfizer Investigational Site, Poznan, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Wroclaw, Poland|Pfizer Investigational Site, Zabrze, Poland|Pfizer Investigational Site, Aveiro, Portugal|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Porto, Portugal|Pfizer Investigational Site, Vila Franca de Xira, Portugal|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Bratislava, Slovakia|Pfizer Investigational Site, Kosice, Slovakia|Pfizer Investigational Site, Bern, Switzerland|Pfizer Investigational Site, Genève, Switzerland|Pfizer Investigational Site, Mendrisio, Switzerland|Pfizer Investigational Site, Zürich, Switzerland|Pfizer Investigational Site |
| URL: | https://clinicaltrials.gov/show/NCT00442325 |
